<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096315</url>
  </required_header>
  <id_info>
    <org_study_id>POL7080-002</org_study_id>
    <nct_id>NCT02096315</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.</brief_title>
  <official_title>A Phase II, Open-label, Multicenter Study to Assess the Tolerance, Safety, Efficacy and Pharmacokinetics/Pharmacodynamics (PK/PD) of POL7080 in the Treatment of Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection Requiring Intravenous Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyphor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyphor Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis
      bronchiectasis caused by Pseudomonas aeruginosa infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be recruited after written informed consent.

        -  Adverse events will be coded using Medical Dictionary for regulatory activities
           (MedDRA).

        -  Descriptive statistics will be used for all the safety and efficacy variables.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum bacterial clearance</measure>
    <time_frame>Day 4, Day 5, Day 10, Day 15 and Day 20</time_frame>
    <description>Reduction in CFU/mL (colony forming units/mL) of Pseudomonas aeruginosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Daily assessment up to 20 days from informed consent.</time_frame>
    <description>Number of adverse events reported by the patients or observed by the investigator will be recorded. Onset, end date, severity, causal relationship, outcome and measures taken will be summarized. Death, discontinuations and serious adverse events will be listed and narrative summaries will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory abnormalities.</measure>
    <time_frame>Day 4, Day 10, Day 15 and Day 20</time_frame>
    <description>The number and severity of abnormal blood chemistry and hematology findings will be summarized descriptively and compared to baseline. Clinically significant values/outliers will be listed and commented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of sputum in 24 hours</measure>
    <time_frame>Day 4, Day 10, Day 15 and Day 20</time_frame>
    <description>Reduction in 24 hours sputum volume as compared to baseline will be computed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To measure the plasma concentrations of POL7080</measure>
    <time_frame>Day 3</time_frame>
    <description>Blood samples to measure POL7080 concentrations before, during and after administration of POL7080</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiectasis</condition>
  <condition>Lower Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>POL7080</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POL7080 administered daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POL7080</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>POL7080</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged â‰¥18 to &lt;80 years and suffering from exacerbation of non-cystic
             fibrosis bronchiectasis due to Pseudomonas aeruginosa infection

          2. Sputum sample collected for culture before starting treatment

        Exclusion Criteria:

          1. Female patients who are pregnant or breast feeding or unwilling to follow reliable
             method of contraception

          2. Subjects suffering from cystic fibrosis, active pulmonary mycobacterial infection, end
             stage chronic obstructive pulmonary disease on long term oxygen therapy, severe
             uncontrolled asthma, active sarcoidosis and active allergic broncho-pulmonary
             aspergillosis

          3. Current exacerbation of bronchiectasis is associated with lung abscess or empyema

          4. Current exacerbation episode is suspected or documented to be due to pathogens other
             than Pseudomonas aeruginosa

          5. Patients with known HIV infection with CD4+ (cluster of differentiation 4) cell count
             &lt; 200/mm3

          6. Patients who are currently enrolled in, or have not yet completed at least 30 days
             since ending another investigational device or drug trial or are receiving other
             investigational agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Polverino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic, Barcelona, SPAIN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Hill, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Infirmary, Edinburgh, U.K.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary</name>
      <address>
        <city>City of Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POL7080</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Non cystic fibrosis bronchiectasis</keyword>
  <keyword>Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

